Q1 Adjusted Net Income Drops 36% Amid Rising Leverage and Key Contract Non-Renewal

summarizeSummary

MEXICAN ECONOMIC DEVELOPMENT INC reported mixed Q1 2026 results, with consolidated revenue and operating income growth overshadowed by a 36.4% decline in adjusted net income and increased leverage, alongside a material contract non-renewal in its Health segment.

check_boxKey Events

• Mixed Q1 2026 Financial Results

  Consolidated revenues grew 6.1% (8.5% comparable) and income from operations increased 5.5% (12.1% comparable). However, net consolidated income, excluding a one-time gain from the BradyPLUS and Imperial Dade merger, declined significantly by 36.4% due to higher financing expenses and the absence of discontinued operations income.

• Increased Leverage

  The Net Debt / EBITDA (ex-KOF) ratio rose to 1.24x from 0.69x in 1Q25, reflecting cash outflows related to ordinary and extraordinary dividends, as well as Ps. 16,055 million in share repurchases over the last twelve months.

• Material Contract Non-Renewal in Health Segment

  Cruz Verde Colombia, the company's health business in Colombia, decided not to renew a medication dispensing agreement under the Mandatory Health Plan (PBS) with EPS Sanitas, which is scheduled to expire on September 30, 2026.

• Varied Segment Performance

  OXXO Mexico and Americas & Mobility segments showed strong growth in revenues and operating income, while Coca-Cola FEMSA faced a softer consumer environment in Mexico, and the Health segment experienced challenging results in Mexico.

auto_awesomeAnalysis

MEXICAN ECONOMIC DEVELOPMENT INC reported mixed Q1 2026 results. While consolidated revenues and operating income showed growth, the underlying net income, excluding a one-time gain from a merger, declined significantly by 36.4%. This decline was primarily due to higher financing expenses and the absence of income from discontinued operations. Furthermore, the company's leverage increased, with the Net Debt / EBITDA (ex-KOF) ratio rising from 0.69x to 1.24x, reflecting substantial cash outflows for dividends and share repurchases. Operationally, the Health segment faces a material risk with the non-renewal of a key medication dispensing agreement in Colombia. Investors should monitor the impact of increased financing costs, rising leverage, and the operational changes in the Health segment, especially following the recent disclosure of a material weakness in internal controls.